COMPARE · Data as of August 14, 2026
BHC vs ETON
Verdict: Side-by-side breakdown using the Bull Rankings model. BHC scored 71.3, ETON scored 72.0 — ETON leads.
Compare another set
BHC
Bausch Health Companies Inc.
71.3
$6.51 · $2.4B
fundamentals as of
Score gap
0.7
ETON leads
ETON
Eton Pharmaceuticals, Inc.
72
$58.86 · $1.7B
fundamentals as of
The model, pillar by pillar (0–100 each)
BHC
stronger →← stronger
ETON
63
Qualityreturns · margins · balance sheet
76
64
Growthrevenue & earnings expansion
100
90
Valuevaluation vs sector peers
50
ETON is stronger on 2 of 3 pillars.
Fundamentals, head-to-head
BHC
ETON
$1.4bC+
FCF
$15mC-
+10.1%B
Rev
+81.5%A
—
D/E
1.02C
0.2xA
P/S
—
0.01A
PEG
1.40B
—
P/E
150.9xD
Winner per row is the stronger grade in our model; a tie or a missing value shows no highlight.
Valuation · DCF cross-check
BHC
ETON
86% below
Price vs fair valuelower is cheaper
335% above
decline
Growth the price implies10-yr FCF · lower = less priced in
~54%/yr
+698%
1-yr DCF upside
-83%
+617%
5-yr DCF upside
-77%
+519%
10-yr DCF upside
-65%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
BHC
Why this score
- Short track record
ETON
Why this score
- Short track record
The companies
BHCBausch Health Companies Inc.
Why now
Drug Manufacturers - Specialty & Generic · market cap $2.4b. Down 23% from 52-week high of $8.44 — deep drawdown territory. Revenue growing +10%, comfortably above the S&P median. PEG 0.01 — paying under fair value for the growth rate. 5 sell-side analysts rate this a Hold with a mean 1-yr target of $7.50 (implying +15% upside).
Moat
ROE 62% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Currently unprofitable (margin -10.1%) — path to GAAP profitability is the core thesis risk. Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
ETONEton Pharmaceuticals, Inc.
Why now
Drug Manufacturers - Specialty & Generic · market cap $1.7b. Trading near 52-week high of $59.79 — momentum setup, limited technical margin of safety. Revenue growing +81% — in hypergrowth territory. 3 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $62.33 (implying +6% upside).
Moat
Net margin 12% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 27% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 116% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Trailing P/E 150.9x prices in sustained high growth — any quarter that disappoints triggers sharp re-rating. Trading within 2% of the 52-week high — limited technical margin of safety; a momentum reversal would test conviction. P/S 15.9x embeds aggressive forward growth — disappointing top-line guidance would compress the multiple hard.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where BHC and ETON diverge
On the headline score the gap is 0.7 points in favor of ETON. They get there differently, though — each leads on a different pillar, so the better pick depends on which you weight.
- ValueBHC 90.5 · ETON 50.0BHC +40.5
- GrowthBHC 63.7 · ETON 100.0ETON +36.3
- QualityBHC 62.9 · ETON 75.6ETON +12.7
Pillars run 0–100 against sector peers, so a score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.